sabizabulin — FDA meeting
Q4 2026
We will first seek regulatory clarity from the FDA through a preIND meeting in calendar Q4 2026 to better understand the scope of the clinical trial.Source filing
VERU biotech catalysts & pipeline
VERU INC · Data as of 2026-10-25
Upcoming catalysts
enobosarm — Interim data
Q1 2027
Phase 2b PLATEAU clinical trial interim analysis near term milestone calendar Q1 2027, clinical supply agreement with Novo Nordisk, strong IP protection with newly issued patent for enobosarm with GLP-1 RA until late 2044—Source filing
enobosarm — Topline data
Q4 2027
Final topline clinical data is expected in the fourth quarter of calendar year 2027.Source filing